These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 28948002)

  • 41. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?
    Asrih M; Jornayvaz FR
    Mol Cell Endocrinol; 2015 Dec; 418 Pt 1():55-65. PubMed ID: 25724480
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association between renin-angiotensin-aldosterone system blockers and postoperative atrial fibrillation in patients with mild and moderate left ventricular dysfunction.
    Ozaydin M; Varol E; Türker Y; Peker O; Erdoğan D; Doğan A; Ibrişim E
    Anadolu Kardiyol Derg; 2010 Apr; 10(2):137-42. PubMed ID: 20382613
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis.
    Schuppan D; Gorrell MD; Klein T; Mark M; Afdhal NH
    Liver Int; 2010 Jul; 30(6):795-808. PubMed ID: 20624207
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Non-alcoholic fatty liver disease.
    Smith BW; Adams LA
    Crit Rev Clin Lab Sci; 2011; 48(3):97-113. PubMed ID: 21875310
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tracing the origins of postoperative atrial fibrillation: the concept of oxidative stress-mediated myocardial injury phenomenon.
    Elahi MM; Flatman S; Matata BM
    Eur J Cardiovasc Prev Rehabil; 2008 Dec; 15(6):735-41. PubMed ID: 19020458
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association of hypoadiponectinemia with non-alcoholic fatty liver disease in urban south Indians--(CURES - 81).
    Gokulakrishnan K; Anjana RM; Indulekha K; Anuradha S; Mohan V
    Indian J Med Res; 2010 Sep; 132():271-7. PubMed ID: 20847373
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Insulin resistance and oxidative stress interdependency in non-alcoholic fatty liver disease.
    Videla LA; Rodrigo R; Araya J; Poniachik J
    Trends Mol Med; 2006 Dec; 12(12):555-8. PubMed ID: 17049925
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Possible molecular mechanisms by which angiotensin II type 1 receptor blockers (ARBs) prevent the development of atrial fibrillation in insulin resistant patients.
    Yamagishi SI; Matsui T; Nakamura K
    Horm Metab Res; 2008 Sep; 40(9):640-4. PubMed ID: 18792876
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Presence of atrial fibrillation is associated with liver stiffness in an elderly Finnish population.
    Käräjämäki AJ; Kettunen O; Lepojärvi S; Koivurova OP; Kesäniemi YA; Huikuri H; Ukkola O
    PLoS One; 2017; 12(3):e0173855. PubMed ID: 28288202
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Atrial Fibrillation and Hypertension: Mechanistic, Epidemiologic, and Treatment Parallels.
    Ogunsua AA; Shaikh AY; Ahmed M; McManus DD
    Methodist Debakey Cardiovasc J; 2015; 11(4):228-34. PubMed ID: 27057292
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Younossi ZM
    Aliment Pharmacol Ther; 2008 Jul; 28(1):2-12. PubMed ID: 18410557
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Atrial fibrillation and atrial fibrosis.
    Tan AY; Zimetbaum P
    J Cardiovasc Pharmacol; 2011 Jun; 57(6):625-9. PubMed ID: 21633248
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches.
    Schuppan D; Schattenberg JM
    J Gastroenterol Hepatol; 2013 Aug; 28 Suppl 1():68-76. PubMed ID: 23855299
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Iron and non-alcoholic fatty liver disease.
    Britton LJ; Subramaniam VN; Crawford DH
    World J Gastroenterol; 2016 Sep; 22(36):8112-22. PubMed ID: 27688653
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hypertension: Potential Player in Cardiovascular Disease Incidence in Preeclampsia.
    Amini P; Amrovani M; Nassaj ZS; Ajorlou P; Pezeshgi A; Ghahrodizadehabyaneh B
    Cardiovasc Toxicol; 2022 May; 22(5):391-403. PubMed ID: 35347585
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Is there a role of lipid-lowering therapies in the management of fatty liver disease?
    Tzanaki I; Agouridis AP; Kostapanos MS
    World J Hepatol; 2022 Jan; 14(1):119-139. PubMed ID: 35126843
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Non-Alcoholic Fatty Liver Disease and Cardiovascular Comorbidities: Pathophysiological Links, Diagnosis, and Therapeutic Management.
    Jichitu A; Bungau S; Stanescu AMA; Vesa CM; Toma MM; Bustea C; Iurciuc S; Rus M; Bacalbasa N; Diaconu CC
    Diagnostics (Basel); 2021 Apr; 11(4):. PubMed ID: 33921359
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nonalcoholic fatty liver disease and atrial fibrillation: possible pathophysiological links and therapeutic interventions.
    Haghbin H; Gangwani MK; Ravi SJK; Perisetti A; Aziz M; Goyal H; Nawras A; Sodeman T
    Ann Gastroenterol; 2020; 33(6):603-614. PubMed ID: 33162737
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The risk of atrial fibrillation in patients with non-alcoholic fatty liver disease and a high hepatic fibrosis index.
    Park HE; Lee H; Choi SY; Kim HS; Chung GE
    Sci Rep; 2020 Mar; 10(1):5023. PubMed ID: 32193478
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nonalcoholic Fatty Liver Disease Is Associated with Increased Atrial Fibrillation Risk in an Elderly Chinese Population: A Cross-Sectional Study.
    Zhang Y; Li P; Miao M; Liu Y; Pan Y; Xu L; Zhu Z; Xu C; Xu L
    Biomed Res Int; 2018; 2018():5628749. PubMed ID: 30112401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.